Nanobiotix' Partner PharmaEngine Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia
Paris, France and Cambridge, Mass, USA, Nov 07, 2016 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October. The trial is evaluating the optimal dose, safety and preliminary efficacy of Nanobiotix's lead product.
PharmaEngine has broadened its development plan for NBTXR3 by launching this new trial in Asia targeting a new and larger head and neck cancer patient population. This follows the successful results from the European Phase I/II trial in patients with head and neck cancers presented in July 2016 by Nanobiotix demonstrating promising signs of tumor volume response and excellent signs of safety.
NBTXR3 is now addressing a wide range of head and neck cancers patients. The study in Asia by PharmaEngine addresses patients receiving chemotherapy (cisplatin) plus radiotherapy whereas the study in Europe by Nanobiotix covers patients which are not eligible for chemotherapy plus radiotherapy and only receive radiotherapy.
Head and neck cancers include cancers of the oral cavity, tongue and oropharynx. These cancers are a major concern for public health, with a high worldwide prevalence, particularly in Asia, where the patient population is expanding.
This joint approach by Nanobiotix and PharmaEngine supports the preparation of a development plan for head and neck cancers registration studies with NBTXR3 potentially in Europe, in the US and in Asia. Nanobiotix will provide this next year.
Laurent Levy, CEO of Nanobiotix commented: "This seventh trial opens significant potential market opportunities for NBTRX3 by broadening the potential treatable population of head and neck cancer patients for whom NBTXR3 may significantly improve quality of life."
About the PharmaEngine Head and Neck Phase I/II Trial in Asia
This new trial is an open-label, single arm, non-randomized study for patients with head and neck cancers. The primary objectives of the study are to determine the optimal dose, safety and preliminary efficacy of NBTXR3 through intra-tumor injection in combination with concurrent chemoradiotherapy (CCRT). The first patient was injected with NBTXR3 in October 2016 and the maximum number of patients that will be enrolled in the study is 42.
About Nanobiotix and PharmaEngine Partnership
PharmaEngine has a licensing agreement with Nanobiotix for the development and commercialization of Nanobiotix's lead product, NBTXR3, in Asia-Pacific. As part of this agreement, Nanobiotix has already received upfront payments and milestone payments.
The Company is eligible to receive further development and commercialization milestone payments. Collectively, these payments may amount to a total of US$56 million plus tiered, up to double-digit royalties on all net product sales in the Asian-Pacific region.
About NANOBIOTIX - www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.
Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma, head and neck cancer, prostate cancer, and liver cancers (HCC and liver metastases) as well as head and neck and rectal cancers under trial by PharmaEngine. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.
Contact
Nanobiotix Sarah Gaubert Head of Communication and Public Affairs +33 (0)1 40 26 07 55 contact@nanobiotix.com
Media relations
France - Springbok Marina Rosoff +33 (0)6 11 58 00 34 marina@springbok.fr
EU Outside France - Instinctif Partners Melanie Toyne Sewell +44 (0) 207 457 2020 nanobiotix@instinctif.com
United States - The Ruth Group Kirsten Thomas / Chris Hippolyte +1 508-280-6592 / +1 646-536-7023 Nanobiotix@theruthgroup.com
Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorite des Marches Financiers) under number D.16-0732 on July 22, 2016 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.
###
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: NANOBIOTIX via Globenewswire
Source: Nanobiotix Sectors: Science & Research, BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
Fujitsu chosen for GENIAC project, starts development of large language models for logical reasoning May 17, 2024 14:03 JST
| NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud May 17, 2024 11:19 JST
| Honda and IBM sign Memorandum of Understanding to Explore Long-term Joint Research and Development of Semiconductor Chip and Software Technologies for Future Software-Defined Vehicles May 15, 2024 14:30 JST
| Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status May 15, 2024 11:19 JST
| SMEIC Proposes to Acquire Shanghai Prime: A Catalyst for Developing a New Dual-Wheel Driver Pattern May 14, 2024 21:54 JST
| DENSO and Certhon Introduce Artemy, A Fully Automated Cherry Truss Tomato Harvesting Robot May 14, 2024 11:02 JST
| Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings May 13, 2024 18:32 JST
| Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures May 13, 2024 17:06 JST
| Ogier and TOYOTA GAZOO Racing triumph again May 13, 2024 14:36 JST
| Spa points haul for TOYOTA GAZOO Racing May 13, 2024 13:56 JST
| DOCOMO to Launch NTT DOCOMO GLOBAL for Global Expansion May 10, 2024 18:13 JST
| Release of "Fugaku-LLM" - a large language model trained on the supercomputer "Fugaku" May 10, 2024 12:20 JST
| Paltalk, Inc. Reports Slight Increase in Revenue and 33% Reduction in Net Loss for First Quarter 2024 May 09, 2024 20:39 JST
| Cordlife Accelerates Lab and Technical Staff Recruitment to Rebuild Foundation and Strengthen Core Processes in Singapore May 09, 2024 19:00 JST
| Honda Opens New R&D Facility in Bengaluru to Accelerate Electrification in India May 09, 2024 14:13 JST
| Fujitsu introduces "explainable AI" for use in genomic medicine and cancer treatment planning May 09, 2024 10:41 JST
| Mitsubishi Heavy Industries Increases Dividends on Back of Historically High FY2023 Results, Releases FY2024 Guidance May 08, 2024 14:27 JST
| Rome becomes the first European city to offer open loop transit payments to JCB Cardmembers May 08, 2024 12:00 JST
| NEC X Invests in Public Safety Startup Multitude Insights, Scaling AI-Powered Collaboration and Information Sharing for Law Enforcement May 08, 2024 10:24 JST
| ServiceNow and Fujitsu announce strategic commitment to launch innovative cross-industry solutions May 08, 2024 08:52 JST
|
More Latest Release >>
|